Abstract
Background COVID-19 can course with respiratory and extrapulmonary disease. SARS-CoV-2 RNA is detected in respiratory samples but also in blood, stool and urine. Severe COVID-19 is characterised by a dysregulated host response to this virus. We studied whether viral RNAemia or viral RNA load in plasma are associated to severe COVID-19 and also to this dysregulated response.
Methods 250 patients with COVID-19 were recruited (50 outpatients, 100 hospitalised ward patients, and 100 critically ill). Viral RNA detection and quantification in plasma was performed using droplet digital PCR, targeting the N1 and N2 regions of the SARS-CoV-2 nucleoprotein gene. The association between SARS-CoV-2 RNAemia and viral RNA load in plasma with severity was evaluated by multivariate logistic regression. Correlations between viral RNA load and biomarkers evidencing dysregulation of host response were evaluated by calculating the Spearman correlation coefficients.
Results the frequency of viral RNAemia was higher in the critically ill patients (78%) compared to ward patients (27%) and outpatients (2%) (p<0.001). Critical patients had higher viral RNA loads in plasma than non-critically ill patients, with non survivors showing the highest values. When outpatients and ward patients were compared, viral RNAemia did not show significant associations in the multivariate analysis. In contrast, when ward patients were compared with ICU patients, both viral RNAemia and viral RNA load in plasma were associated with critical illness (OR [CI 95%], p): RNAemia (3.92 [1.183 - 12.968], 0.025), viral RNA load (N1) (1.962 [1.244 - 3.096], 0.004); viral RNA load (N2) (2.229 [1.382 - 3.595], 0.001). Viral RNA load in plasma correlated with higher levels of chemokines (CXCL10, CCL2), biomarkers indicative of a systemic inflammatory response (IL-6, CRP, Ferritin), activation of NK cells (IL-15), endothelial dysfunction (VCAM-1, angiopoietin-2, ICAM-1), coagulation activation (D-Dimer and INR), tissue damage (LDH, GPT), neutrophil response (neutrophils counts, myeloperoxidase, GM-CSF) and immunodepression (PD-L1, IL-10, lymphopenia and monocytopenia).
Conclusions SARS-CoV-2 RNAemia and viral RNA load in plasma are associated to critical illness in COVID-19. Viral RNA load in plasma correlates with key signatures of dysregulated host responses, suggesting a major role of uncontrolled viral replication in the pathogenesis of this disease.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04457505
Funding Statement
This work was supported by awards from the Canadian Institutes of Health Research, the Canadian 2019 Novel Coronavirus (COVID-19) Rapid Research Funding initiative (CIHR OV2 170357), Research Nova Scotia (DJK), Atlantic Genome/Genome Canada (DJK), Li-Ka Shing Foundation (DJK), Dalhousie Medical Research Foundation (DJK), the Subvenciones de concesion directa para proyectos y programas de investigacion del virus SARS-CoV2, causante del COVID-19, FONDO - COVID19, Instituto de Salud Carlos III (COV20/00110, CIBERES, 06/06/0028), (AT) and finally by the Convocatoria extraordinaria y urgente de la Gerencia Regional de Salud de Castilla y Leon, para la financiacion de proyectos de investigacion en enfermedad COVID-19 (GRS COVID 53/A/20) (CA). DJK is a recipient of the Canada Research Chair in Translational Vaccinology and Inflammation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Comite de Etica de la Investigacion con Medicamentos del Area de Salud de Salamanca, code PI 2020 03 452
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We provide now viral load quantification in plasma from patients with COVID-19 by using droplet digital PCR, method which replace the microarrays used in the previous version. Some new biomarkers are added, to evaluate their correlation with viral load in plasma.
Data Availability
Data are available upon reasonable request
List of abbreviations
- SARS-CoV-2
- Severe acute Respiratory Syndrom-Coronavirus-2
- LDH
- Lactate dehydrogenase
- SF
- Granulocyte colony-stimulating factor
- TLR
- toll like receptor